CYFRA 21-1 As a Predictor to Response to Chemotherapy and Overall Survival in Patients with Advanced NSCLC

被引：0
|
作者：
Lqbal, K. [1 ]
机构：
[1] Oncol & Radiotherapy Inst, Oncol Nucl Med, Islamabad, Pakistan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
CYFRA; 21-1; ADVANCED NSCLC; OVERALL SURVIVAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-44
引用
收藏
页码：S884 / S884
页数：1
相关论文
共 50 条
  • [1] Early CYFRA 21-1 variation, response to chemotherapy, and survival, in loccaly advanced NSCLC
    Merle, P
    Janicot, H
    Filaire, M
    Roux, D
    Bailly, C
    Vincent, C
    Tchirkov, A
    Escnde, G
    Caillaud, D
    Verrelle, P
    LUNG CANCER, 2005, 49 : S284 - S284
  • [2] Prognostic Value of RDW, NLR and CYFRA 21-1 in Overall Survival of Patients with Metastatic NSCLC
    Flores, C. J.
    Aguilar, A.
    Mas, L.
    Enriquez, D.
    Gutierrez, J. M.
    Schwarz, L.
    Vallejos, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S875 - S875
  • [3] Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
    Svaton, Martin
    Blazek, Jiri
    Krakorova, Gabriela
    Pesek, Milos
    Buresova, Marcela
    Teufelova, Zuzana
    Vodicka, Josef
    Hurdalkova, Karolina
    Barinova, Magda
    Topolcan, Ondrej
    ANTICANCER RESEARCH, 2021, 41 (04) : 2053 - 2058
  • [4] Combined Prognostic Value of CYFRA 21-1 and CEA in Overall Survival of Patients with III-IV Clinical Stage NSCLC
    Flores, C. J.
    Aguilar, A.
    Mas, L.
    Enriquez, D.
    Gutierrez, J. M.
    Schwarz, L.
    Vallejos, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1082 - S1082
  • [5] CEA AND CYFRA 21-1 AS AN EARLY PREDICTOR TO RESPONSE TO FIRST LINE CHEMOTHERAPY IN ADVANCED NON SMALL CELL LUNG CANCER
    Iqbal, Kashif
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1248 - S1249
  • [6] Value of CYFRA 21-1 as determinant of survival and predictor of disease course in lung cancer patients
    Barradas, P
    Costa, A
    Cristovao, M
    Fragoso, AL
    Alves, P
    Melo, MJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S257 - S257
  • [7] Serum Cyfra 21-1 as a co-variable in future NSCLC chemotherapy trials
    Watine, J
    LUNG CANCER, 2001, 33 (01) : 89 - 91
  • [8] Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Benesova, Lucie
    Minarik, Marek
    Bortlicek, Zbynek
    Topolcan, Ondrej
    ANTICANCER RESEARCH, 2014, 34 (06) : 3205 - 3210
  • [9] What is the clinical significance of increased serum CYFRA 21-1 and CEA concentrations in the patients with advanced NSCLC?
    Szturmowicz, M
    Zaleska, M
    Zych, J
    Roszkowska, B
    Langfort, R
    Demkow, U
    Roszkowski-Sliz, K
    CHEST, 2004, 126 (04) : 913S - 913S
  • [10] Serum CEA but not Cyfra 21-1 concentration is an independent prognostic factor in advanced NSCLC
    Szturmowicz, M
    Zaleska, M
    Zych, J
    Roszkowska, B
    Langfort, R
    Demkow, U
    Bestry, I
    Roszkowski-Sliz, K
    LUNG CANCER, 2004, 45 : S29 - S29
12345